Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer

Conclusions: These data support the further development of the 806-PE38 immunotoxin as a therapeutic agent for the treatment of patients with EGFR-positive TNBC. Follow-up experiments with combination therapies will be attempted to achieve full remissions.

Source: JNCI - April 12, 2016 Category: Cancer & Oncology Authors: Simon, N., Antignani, A., Sarnovsky, R., Hewitt, S. M., FitzGerald, D. Tags: Article Source Type: research